[Early efficacy of recombinant human erythropoietin in treatment of anemia].
A Before-after study based on self-comparison was conducted to assess the early efficacy of recombinant human erythropoietin (r-HuEPO) in 51 patients with uremic anemia who were subjected to dialyses. A significant elevation of levels of Hb and Hct was observed (P < 0.001, P < 0.005) after r-HuEPO therapy. And hemorheologic tests showed whole blood viscosity was obviously increased (P < 0.005), but no changes in plasmic viscosity and platelet adhesion rate were found (P > 0.05). No increase of blood pressure of the patients was noticed in the early period after treatment. The results revealed a satisfactory early efficacy with few sideeffects of the r-HuEPO treatment in uremic anemia.
Huang
S
S
Department of Kidney Internal Medicine, First Affiliated Hospital, Chengdu.
Yang
L
L
Huang
M
M
D000328:Adult; D000740:Anemia / Q000628:therapy*; D001809:Blood Viscosity; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006400:Hematocrit; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D014511:Uremia / Q000150:complications
D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin